

# **Bkina**

THE COMBINED ACTION **OF THE THREE SPECIES OF ECHINACEA RESPECTING THE ORIGINAL PHYTOCOMPLEX** FOR A TOTAL IMMUNOMODULANT AND ANTIMICROBIAL ACTION

PURPURE



## Echinacea: an extraordinary phytochemical complexity and a wide variety of products

The commercially available extracts from Echinacea differ in:

- > Medicinal species (E. purpurea, E. angustifolia, E. pallida)
- > Part of the plant (roots, aerial parts)
- > Storage conditions and transformative process

These variables strongly influence the nature and the content of phytochemicals substances present in the final product: the Echinacea phytochemical pattern is variable depending on the species and the drug considered (see Table 1), while storage conditions, drying and extractive methods may affect the integrity of the original phytocomplex.[1-5]

> The extracts usually present on the market are from dried plants, obtained from one or two species of Echinacea with echinacoside or polysaccharides assay, even if nowadays a great importance is given to the alkylamide fraction and more generally to the entire phytocomplex for therapeutical purposes.[6-7]

Tabella 1. Quali-quantitative variation of phytochemical compounds in relation to the species and the drug of Echinacea.[8-17]

	E. PURPUREA	E. ANGUSTIFOLIA	E. PALLIDA		
POLYSACCHARIDES (POLAR FRACTION)					
HETEROXYLANS (PS-I) AND ARABINORHAMNOGALACTANS (PS-II)	++++ (aerial parts)	absent	absent		
CAFFEIC ACID DERIVATES (MEDIUM POLARITY FRACTION)					
ECHINACOSIDE	absent	++++ (aerial parts and roots)	++++ (aerial parts and roots)		
CICHORIC ACID	++++ (aerial parts and roots)	traces	++++ (aerial parts)		
CINARIN	absent	++++ (roots)	absent		
LIPOPHILIC COMPOUNDS (APOLAR FRACTION)					
ALKYLAMIDES (Echinacein and isomers dodeca-2,4,8,10- tetraenoic acid isobutylamide)	++++ (aerial parts and roots)	++++ (aerial parts and roots)	++++ (aerial parts)		
POLYINES	absent	absent	++++ (roots)		

	E. PURPUREA	E. ANGUSTIFOLIA	E. PALLIDA		
POLYSACCHARIDES (POLAR FRACTION)					
HETEROXYLANS (PS-I) AND ARABINORHAMNOGALACTANS (PS-II)	++++ (aerial parts)	absent	absent		
CAFFEIC ACID DERIVATES (MEDIUM POLARITY FRACTION)					
ECHINACOSIDE	absent	++++ (aerial parts and roots)	++++ (aerial parts and roots)		
CICHORIC ACID	++++ (aerial parts and roots)	traces	++++ (aerial parts)		
CINARIN	absent	++++ (roots)	absent		
LIPOPHILIC COMPOUNDS (APOLAR FRACTION)					
ALKYLAMIDES (Echinacein and isomers dodeca-2,4,8,10- tetraenoic acid isobutylamide)	++++ (aerial parts and roots)	++++ (aerial parts and roots)	++++ (aerial parts)		
POLYINES	absent	absent	++++ (roots)		



## <u> 3kina</u>



### **Properly designed** and developed to provide high efficacy and quality

Ekina3 is a dried extract made up of a calibrated mix of the three Echinacea medical species

(E. purpurea, E. angustifolia, E. pallida) and it's obtained directly from fresh plants. The Echinacea plants are grown and processed in Italy.

Use of the three Echinacea species and different parts of the same species (roots, aerial parts)

Complementary action and mutual enhancement of Echinacea genus active principles

Careful plants selection and harvesting during the proper balsamic time

Starting plant material with a high content of actives

**Extraction directly** from fresh plants (no drying) immediately started after harvest

Maintenance of thermolabile and easily degradable substances

**Double extraction** in purified water and in hydroalcoholic solvent


Extraction of both polar and no-polar fractions

Use of **thin-film high vacuum concentrator** that reduces exposure to heat sources

Maintenance of thermolabile and easily degradable substances

## The three Echinacea mix: synergistic action of all active ingredients

Ekina3 is made up of the three Echinacea species using roots and/or aerial parts granting the synergistic action of all actives:



### **IMMUNOMODULANT ACTIVITY** [12,18-24] ALKYLAMIDES, CICHORIC ACID, POLYSACCHARIDES

> Phagocytosis activation by neutrophils and macrophages (alkylamides, cichoric acid, heteroxylan PS-I) > Cytotoxic activity stimulation of macrophages with release of TNF-α, IL-1 and IL-6 (arabinorhamnogalactan PS-II) > Natural Killer cell activity stimulation due to reduced production of prostaglandins and leukotrienes (alkylamides)

### ANTIMICROBICAL ACTIVITY [12,25-28] ECHINACOSIDE, CICHORIC ACID, POLYSACCHARIDES, POLYINES

> Viral receptors inhibition on the cell surface (echinacoside) > Direct inhibition of tissue and bacterial hyaluronidase and indirect inhibition of the hyaluronic acid- hyaluronidase system due to increased fibroblasts activity (cichoric acid, polysaccharides) > Bacteriostatic activity (polyine)

### **ANTI-INFLAMMATORY ACTIVITY** [29-32] ALKYLAMIDES

> Cyclooxygenase and lipoxygenase enzymes inhibition and consequent reduction in the prostaglandins and leukotrienes production > Stimulation of adrenocortical hormones secretion with cortisone-like effect > Interaction with CB2 cannabinoids receptors

## Blina

## Cultivation and harvesting: high content of actives in the starting plants

Echinacea plants are cultivated without the use of synthetic pesticides and fertilizers in agricultural grounds located far away from busy industrial roads.

Roots and aerial parts are collected in the **optimal balsamic time**, when the phytocomplex production is maximum:

• roots > autumn-winter, period of guiescence with the accumulation of secondary metabolites;

• aerial parts > June-July, corresponding to the period of flowering.

## From the harvesting to the finish product: maximum integrity of the phytocomplex

The extraction immediately begins after the harvest.

The use of fresh vegetable matrix guarantees the presence of caffeic acid derivates and alkylamides, molecules which are sensitive to the oxidation processes occurring during drying.[1,3-5]

The double extraction, first in purified water and then in hydroalcoholic solvent, allows the extraction of actives with different polarity: polysaccharides need water, while caffeic acid derivates and alkylamides require alcohol.

The concentration of the solution is made by a **thin-film high vacuum concentrator** that reduces exposure to heat sources enabling to preserve thermolabile and easily degradable substances. The last production stage is the spray-drying. The dried extract\* is solvent free and has a drug/extract ratio (D/E) of 4:1.

> **Ekina3** preserves the ALKYLAMIDES FRACTION wich plays a key role in the Echinacea immunomodulant action.


\*Ekina3 is also available as concentrated aqueous extract (in this case the extractive solution, without the alcohol component, is concentrated to obtain a D/E ratio of 1:2)

## Multiple markers HPLC assay: guaranteed presence of all Echinacea active ingredients

The analysis method has been developed by Padua University Department of Pharmaceutical Sciences.

### Table 2. Phytoconstituents content for 100 g of Ekina3 dried extract standard sample:

CHEMICAL COMPOUND	A S S A Y	METHOD
ECHINACOSIDE	≥ 0,2%	HPLC-DAD
CINARIN	≥ 0,1%	HPLC-DAD
CICHORIC ACID	≥ 0,3%	HPLC-DAD
TOTAL CAFFEIC DERIVATIVES	≥ 2,3%	HPLC-DAD
DODECA ISOBUTYLAMIDE	≥ 0,2%	HPLC-DAD
POLYSACCHARIDES	≥ 14,9%	HPLC-DAD





### Cichoric acid

## **Bkina**

**Ekina3** it's part of the line **Ek**<sup>3</sup> Italian fresh plants by **EKAP** 

### Distributed by:



Nutraceutica S.r.l. Via Idice 270/1 - 40050 Monterenzio (BO) 051.929833; info@nutraceutica.it



**EKAP S.r.l.** Società Agricola Via S. Sosimo 6/m - 24030 Palazzago (BG) 035.549928; info@ekap.it

1. NB Perry et al. Planta Med. 2000; 66:54–6. 2. NB Perry et al. J. Agric. Food Chem. 2001;49(4):1702-106. 3. H Kim et al. J. Agric. Food Chem. 2000;48(9):4182-4186. 4. Kim H et al. J. Agric. Food Chem. 2000;48(9):4187-4192. 5. DE Gray et al. Planta Med. 2003;69:50-55. 6. S Foster. The purple coneflowers. American Botanical Council 1991. 7. K Bone. Alternative Medicine Review 1997;2(2):87-93. 8. R Bauer, P Reminger. Planta Med. 1989; 55: 367-371. 9. R Bauer et al. Z. Phytother. 1989;10. 43-48. 10. R Bauer et al. Phytochem. 1988;27: 2339-2342.8. 11. R Bauer che Apoth. Z. 1988;128: 174-180. 12. R Bauer, H Wagner. Wagner H & Farnswort NR (eds.). Econ. and med. plants res., London, Acad. Press 1991; 253-321. 13. H Becker, W Hsi sch. 1985;40c; 585-587. 14. M Laasonen et al. Planta Med. 2002;68, 572-574. 15. P Pietta et al. Planta Med. 1998;64:649-652. 16. A Proksch, H Wagner. Phytochemistry 1987; et al. Deu 17. V Schulte et al. Arzn. Forsch. 1967;17:825-829. 18. D Melchart et al. Phytomedicine 1994;1:245-254. 19. H Wagner et al. Arzn. Forsch. 1995;35: 1069-1075. 20. RA Burger et al. Int. J. Immunopharm. 1997;19: 371-379. 21. J Rininger et al. J. of Leucocyte Biology 2000; 68(4): 503-510. 22. M Stempel et al. Infection and immunity 1984;845-849. 23. K Woelkart K, R Bauer. Planta Med. 2007;73:615-623. 24. M Brosseau, SC Miller. Biogerentology 2005;6(3):157-163. 25. R Bauer, K Woelkart. "Echinacea" in encyclopedia of dietary supplements, 117-187. New York. 26. FE Koch, H Haase. Arzneimittel-Forschung 1952;2:464-467. 27. RM Facino et al. Farmaco 1993; 48:1447-1461. 28. I Bonadeo et al. Essenze-Profumi-Piante. Officin-Aromi-Sapo ni-Cosmetici-Aerosol 1971;53: 281-295. 29. H Wagner et al. Planta Med. 1989;55. 30. B Muller-Jakic et al. Planta Med. 1994;60:37-40. 31. CA Lalone et al. J. Agric. Food Chem

# Three Echinacea species for the maximum efficacy

Blina

